Asset profile
dexmethylphenidate HCl · Cingulate (CING)
- Indication
- ADHD
- Also known as
- CTx-1301
Company
CINGCingulate
CINGCingulateCingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus…
On the calendar
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04138498 | Phase 1/2 | Completed | Mar 6, 2020 | 45 | 1 of 1 sites in the United States |
| NCT05924594 | Phase 3 | Suspended | Feb 1, 2027 | 45 | 3 of 3 sites in the United States |
| NCT05631626 | Phase 3 | Completed | Jun 13, 2023 | 26 | 1 of 1 sites in the United States |
| NCT05286762 | Phase 3 | Completed | Feb 29, 2024 | 103 | 24 of 24 sites in the United States |